- Home
- CYCN vs TNON Comparison
CYCN vs TNON Comparison
Compare CYCN & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- TNON
- Stock Information
- Founded
- CYCN 2018
- TNON 2012
- Country
- CYCN United States
- TNON United States
- Employees
- CYCN N/A
- TNON N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- TNON Medical Specialities
- Sector
- CYCN Health Care
- TNON Health Care
- Exchange
- CYCN Nasdaq
- TNON Nasdaq
- Market Cap
- CYCN 6.5M
- TNON 6.9M
- IPO Year
- CYCN N/A
- TNON 2022
- Fundamental
- Price
- CYCN $3.18
- TNON $1.00
- Analyst Decision
- CYCN
- TNON Strong Buy
- Analyst Count
- CYCN 0
- TNON 3
- Target Price
- CYCN N/A
- TNON $11.67
- AVG Volume (30 Days)
- CYCN 20.7K
- TNON 257.0K
- Earning Date
- CYCN 05-06-2025
- TNON 05-13-2025
- Dividend Yield
- CYCN N/A
- TNON N/A
- EPS Growth
- CYCN N/A
- TNON N/A
- EPS
- CYCN N/A
- TNON N/A
- Revenue
- CYCN $2,081,000.00
- TNON $3,284,000.00
- Revenue This Year
- CYCN N/A
- TNON $46.26
- Revenue Next Year
- CYCN N/A
- TNON $58.02
- P/E Ratio
- CYCN N/A
- TNON N/A
- Revenue Growth
- CYCN N/A
- TNON 2.18
- 52 Week Low
- CYCN $1.27
- TNON $0.91
- 52 Week High
- CYCN $9.47
- TNON $15.79
- Technical
- Relative Strength Index (RSI)
- CYCN 53.92
- TNON 37.47
- Support Level
- CYCN $3.04
- TNON $0.98
- Resistance Level
- CYCN $3.26
- TNON $1.35
- Average True Range (ATR)
- CYCN 0.25
- TNON 0.05
- MACD
- CYCN 0.01
- TNON -0.00
- Stochastic Oscillator
- CYCN 80.00
- TNON 9.52
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.